I was hoping to get something out prior to Christmas, but I will now likely announce which stock my next article will address a week or two after Christmas. I plan to have an article completed by mid-January. It's underway, and as the holiday approaches I'll have a bit more time to research. It's a pretty good bet due to the low risk, potential for a large gain, and the fact that low volume seems to be pushing the price further downward (therefore making it an even better pick!).
I also plan to re-visit Neuralstem (NYSEMKT:CUR) if time permits. Specifically, I'd like to share some thoughts and insights into the Phase 2 ALS trials. I want to steer clear of the NSI-189 results, so I imagine something next month is more likely. Note that I don't think NSI-189 will be bad, but I don't want to recommend it with an article on the ALS trial when the depression drug results (189) could have a material impact on the stock in the very near term. Best of luck to all Neuralstem longs. I continue to like what I see in the pipeline there!